LACIE THEIS: Open Payments
NPI 1871105916 · WAVERLY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,622 in 167 payments from 15 companies in 2025. Trend: 2023 $1,811 · 2024 $2,021 · 2025 $2,622
Food & beverage: $2,399Education: $223
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 52 | $428 |
| Teva Pharmaceuticals USA, Inc. | 16 | $427 |
| Otsuka America Pharmaceutical, Inc. | 14 | $241 |
| Alkermes, Inc. | 14 | $210 |
| ABBVIE INC. | 12 | $202 |
| E.R. Squibb & Sons, L.L.C. | 11 | $202 |
| Axsome Therapeutics, Inc. | 6 | $177 |
| Janssen Pharmaceuticals, Inc | 10 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $172 |
| Supernus Pharmaceuticals, Inc. | 12 | $145 |
Products named: INGREZZA, VRAYLAR, COBENFY, ARISTADA, REXULTI, Auvelity, INVEGA SUSTENNA, CAPLYTA.
Industry payments across IA — which companies pay providers there.
